Developing a new method to deliver blood clot-dissolving drugs effectively
Assembly, Dosimetry, and Assessment of a Platform Technology for the Delivery of Thrombolytics
This study is working on a new way to deliver clot-busting medications more effectively and safely to help people who have had a stroke or heart attack.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-11023589 on NIH RePORTER |
What this research studies
This research focuses on creating an innovative platform for delivering thrombolytic drugs, which are used to dissolve blood clots. By utilizing a combination of natural biomolecules and advanced bioengineering techniques, the team aims to enhance the effectiveness of these drugs while ensuring they are safely delivered to the targeted area in the body. The approach involves using the body's circulatory system as a delivery route, allowing for precise drug release at the site of the clot, potentially improving treatment outcomes for patients with conditions like stroke or heart attack.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients who are at risk of or currently experiencing conditions related to blood clots, such as stroke or myocardial infarction.
Not a fit: Patients with conditions that contraindicate the use of thrombolytic therapy or those who do not have blood clot-related issues may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve the effectiveness of thrombolytic therapies, leading to better recovery outcomes for patients experiencing blood clots.
How similar studies have performed: Previous research has shown promising results with similar bioengineering approaches in drug delivery, indicating a potential for success in this novel application.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Lawrence, David S. — Univ of North Carolina Chapel Hill
- Study coordinator: Lawrence, David S.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.